Tumor Lysis Syndrome News and Research

RSS
CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

New personalized cellular therapy approved for use in the European Union

New personalized cellular therapy approved for use in the European Union

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

Combining oral drug with personalized cell therapy can lead to complete remission in CLL patients

Combining oral drug with personalized cell therapy can lead to complete remission in CLL patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD temporarily suspends commercial distribution of Iclusig drug in US